ClinicalTrials.gg
CompletedNCT01631214ARCHUpdated Feb 21, 2025Results posted

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of Romosozumab and Alendronate in Postmenopausal Women With Osteoporosis, sponsored by Amgen. Completed at 317 sites in 42 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,093
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.

Enrollment
2nd of 20
4,093 · median 80
Started
2012
with 3 others
Phase 3
5 of 20
none open now
Registered
3rd of 20
by date
Lead sponsor
8 of 20
Amgen

Among the 20 studies testing romosozumab in Osteoporosis, this one is the 2nd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 3rd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing romosozumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.

Read the detailed description

In this trial, women were randomly assigned in a 1:1 ratio to receive monthly subcutaneous romosozumab or weekly oral alendronate for 12 months. Randomization was stratified according to age (\<75 vs. ≥75 years). After completion of the double-blind treatment period, all the participants were to receive open-label weekly oral alendronate until the end of the trial, with blinding to the initial treatment assignment maintained.

The primary analysis was performed when clinical fracture events had been confirmed in at least 330 participants and all the participants had completed the month 24 visit. The study was to continue in an event-driven manner until at least 440 participants experienced a nonvertebral fracture or if the superiority of romosozumab was proven for nonvertebral fractures at the primary analysis.

03

Conditions studied

  • Postmenopausal Women With Osteoporosis

Keywords

  • Osteoporosis, Osteoporosis-postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

women who meet at least one of the following bone mineral density (BMD) and fracture criteria:

  • BMD T-score at the total hip or femoral neck of ≤ -2.50 and EITHER:

    • at least 1 moderate (semiquantitative grade [SQ]2) or severe (SQ3) vertebral fracture OR
    • at least 2 mild (SQ1) vertebral fractures OR
  • BMD T-score at the total hip or femoral neck of ≤ -2.00 and EITHER:

    • at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures OR
    • a fracture of the proximal femur that occurred within 3 to 24 months prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • History of metabolic or bone disease (except osteoporosis)
  • Use of agents affecting bone metabolism
  • Vitamin D insufficiency
  • History of solid organ or bone marrow transplants
  • Hyper- or hypocalcemia
  • Hyper- or hypothyroidism
  • Hyper- or hypoparathyroidism
  • Possible signs of intolerance to alendronate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,093 participants (actual)

Study arms

  • Active comparator
    Alendronate/Alendronate

    Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.

    Drug: Alendronate · Drug: Placebo to Romosozumab

  • Experimental
    Romosozumab/Alendronate

    Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.

    Biological: Romosozumab · Drug: Alendronate · Drug: Placebo to Alendronate

Interventions

  • BiologicalRomosozumab

    Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.

    Also known as: AMG 785, Evenity

  • Alendronate 70 mg tablet taken once a week

    Also known as: Fosamax

  • DrugPlacebo to Romosozumab

    Administered by subcutaneous injection once a month during the double-blind treatment phase.

  • DrugPlacebo to Alendronate

    Matching placebo tablet taken once a week during the double-blind treatment phase.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With New Vertebral Fractures Through Month 24

    All fracture assessments were performed by blinded central imaging readers. New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.

    Time frame: 24 months

  2. Percentage of Participants With a Clinical Fracture at the Primary Analysis

    All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

Secondary outcomes

  1. Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis

    A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

  2. Percentage of Participants With Any Fracture at the Primary Analysis

    All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.

    Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

  3. Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24

    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.

    Time frame: 24 months

  4. Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis

    Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.

    Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

  5. Percentage of Participants With a Hip Fracture at the Primary Analysis

    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

    Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

  6. Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24

    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.

    Time frame: 24 months

  7. Percentage of Participants With a Clinical Fracture Through Month 24

    Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 24 months

  8. Percentage of Participants With a Nonvertebral Fracture Through Month 24

    A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 24 months

  9. Percentage of Participants With a Hip Fracture Through Month 24

    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

    Time frame: 24 months

  10. Percentage of Participants With a Clinical Vertebral Fracture Through Month 24

    A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.

    Time frame: 24 months

  11. Percentage of Participants With a Clinical Fracture Through Month 12

    Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 12 months

  12. Percentage of Participants With New Vertebral Fractures Through Month 12

    New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader.

    Time frame: 12 months

  13. Percentage of Participants With Any Fracture Through Month 12

    All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.

    Time frame: 12 months

  14. Percentage of Participants With a Nonvertebral Fracture Through Month 12

    A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 12 months

  15. Percentage of Participants With a Hip Fracture Through Month 12

    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

    Time frame: 12 months

  16. Percentage of Participants With a Major Osteoporotic Fracture Through Month 12

    Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 12 months

  17. Percentage of Participants With a Clinical Vertebral Fracture Through Month 12

    A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.

    Time frame: 12 months

  18. Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 24

  19. Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 24

  20. Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 24

  21. Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 12

  22. Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 12

  23. Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 12

  24. Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 36

  25. Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 36

  26. Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 36

07

Results

Posted Dec 12, 2018

Participant flow

The study was conducted at 270 centers in 41 countries globally from 04 May 2012 to 29 June 2017.

Participant flow — Overall Study
MilestoneAlendronate/AlendronateRomosozumab/Alendronate
Started20472046
Received double-blind treatment20402038
Completed double-blind period18231831
Completed primary analysis period15761574
Completed15031523
Not completed544523
Withdrew: Withdrawal by subject276290
Withdrew: Death113106
Withdrew: Lost to follow-up5440
Withdrew: Adverse event4545
Withdrew: Other2219
Withdrew: Noncompliance1615
Withdrew: Requirement for alternative therapy83
Withdrew: Protocol deviation43
Withdrew: Ineligibility determined52
Withdrew: Administrative decision10

Outcome measures

PrimaryPercentage of Participants With New Vertebral Fractures Through Month 24

All fracture assessments were performed by blinded central imaging readers. New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With New Vertebral Fractures Through Month 24
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With New Vertebral Fractures Through Month 248.04.1
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Logistic · p = <0.001 · Odds ratio (or): 0.48 · 95% CI 0.36 to 0.64Values \< 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Risk ratio (rr): 0.50 · 95% CI 0.38 to 0.66SE represents the standard error of log (risk ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Absolute risk reduction: 4.03 · 95% CI 2.50 to 5.57
PrimaryPercentage of Participants With a Clinical Fracture at the Primary Analysis

All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Fracture at the Primary Analysis
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Clinical Fracture at the Primary Analysis13.09.7
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.73 · 95% CI 0.61 to 0.88Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio)
SecondaryPercentage of Participants With a Nonvertebral Fracture at the Primary Analysis

A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Reported as:
Number · percentage of participants
Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis10.68.7
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.040 (The adjusted 2-sided p-value is reported.) · Hazard ratio (hr): 0.81 · 95% CI 0.66 to 0.99Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With Any Fracture at the Primary Analysis

All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.

Time frame:
The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Reported as:
Number · percentage of participants
Percentage of Participants With Any Fracture at the Primary Analysis
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With Any Fracture at the Primary Analysis19.113.0
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.65 · 95% CI 0.56 to 0.76Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a New or Worsening Vertebral Fracture Through Month 24

A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 249.24.8
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Logistic · p = <0.001 · Odds ratio (or): 0.49 · 95% CI 0.37 to 0.64Values \< 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Risk ratio (rr): 0.52 · 95% CI 0.40 to 0.66SE represents the standard error of log (risk ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Absolute risk reduction: 4.44 · 95% CI 2.80 to 6.08
SecondaryPercentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis

Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.

Time frame:
The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Reported as:
Number · percentage of participants
Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis9.67.1
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.004 · Hazard ratio (hr): 0.73 · 95% CI 0.59 to 0.90Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Hip Fracture at the Primary Analysis

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

Time frame:
The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Reported as:
Number · percentage of participants
Percentage of Participants With a Hip Fracture at the Primary Analysis
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Hip Fracture at the Primary Analysis3.22.0
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.015 · Hazard ratio (hr): 0.62 · 95% CI 0.42 to 0.92Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24

A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 242.51.3
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Logistic · p = 0.008 · Odds ratio (or): 0.51 · 95% CI 0.31 to 0.85Values \< 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Risk ratio (rr): 0.52 · 95% CI 0.32 to 0.85SE represents the standard error of log (risk ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Absolute risk reduction: 1.21 · 95% CI 0.33 to 2.10
SecondaryPercentage of Participants With a Clinical Fracture Through Month 24

Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Fracture Through Month 24
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Clinical Fracture Through Month 249.67.1
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.005 · Hazard ratio (hr): 0.74 · 95% CI 0.59 to 0.91Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Nonvertebral Fracture Through Month 24

A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Nonvertebral Fracture Through Month 24
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Nonvertebral Fracture Through Month 247.86.3
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.074 · Hazard ratio (hr): 0.81 · 95% CI 0.64 to 1.02Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Hip Fracture Through Month 24

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Hip Fracture Through Month 24
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Hip Fracture Through Month 242.11.5
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.17 · Hazard ratio (hr): 0.72 · 95% CI 0.46 to 1.15Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Clinical Vertebral Fracture Through Month 24

A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Vertebral Fracture Through Month 24
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Clinical Vertebral Fracture Through Month 242.10.9
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.41 · 95% CI 0.24 to 0.71Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Clinical Fracture Through Month 12

Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Fracture Through Month 12
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Clinical Fracture Through Month 125.43.9
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.027 · Hazard ratio (hr): 0.72 · 95% CI 0.54 to 0.96Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With New Vertebral Fractures Through Month 12

New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With New Vertebral Fractures Through Month 12
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With New Vertebral Fractures Through Month 125.03.2
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Logistic · p = 0.008 · Odds ratio (or): 0.63 · 95% CI 0.44 to 0.89Values \< 1 for odds ratio favor romosozumab. The standard error (SE) represents the standard error of log(odds ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Risk ratio (rr): 0.64 · 95% CI 0.46 to 0.89SE represents the standard error of log (risk ratio).
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Absolute risk reduction: 1.84 · 95% CI 0.51 to 3.17
SecondaryPercentage of Participants With Any Fracture Through Month 12

All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Any Fracture Through Month 12
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With Any Fracture Through Month 129.26.5
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.002 · Hazard ratio (hr): 0.71 · 95% CI 0.57 to 0.88Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Nonvertebral Fracture Through Month 12

A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Nonvertebral Fracture Through Month 12
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Nonvertebral Fracture Through Month 124.63.4
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.057 · Hazard ratio (hr): 0.74 · 95% CI 0.54 to 1.01Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Hip Fracture Through Month 12

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Hip Fracture Through Month 12
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Hip Fracture Through Month 121.10.7
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.19 · Hazard ratio (hr): 0.64 · 95% CI 0.33 to 1.26Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Major Osteoporotic Fracture Through Month 12

Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Major Osteoporotic Fracture Through Month 12
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Major Osteoporotic Fracture Through Month 124.23.0
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.053 · Hazard ratio (hr): 0.72 · 95% CI 0.52 to 1.01Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercentage of Participants With a Clinical Vertebral Fracture Through Month 12

A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Vertebral Fracture Through Month 12
percentage of participantsAlendronate/AlendronateRomosozumab/Alendronate
Percentage of Participants With a Clinical Vertebral Fracture Through Month 120.90.5
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · Regression, Cox · p = 0.14 · Hazard ratio (hr): 0.56 · 95% CI 0.26 to 1.22Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Hazard ratio \< 1 favors romosozumab; SE represents the standard error of log (hazard ratio).
SecondaryPercent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 247.2 ± 0.215.3 ± 0.2
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 8.1 · 95% CI 7.58 to 8.57
SecondaryPercent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 243.5 ± 0.17.2 ± 0.1
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 3.8 · 95% CI 3.42 to 4.10
SecondaryPercent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 242.3 ± 0.26.0 ± 0.2
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 3.8 · 95% CI 3.40 to 4.14
SecondaryPercent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 125.0 ± 0.113.7 ± 0.2
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 8.7 · 95% CI 8.31 to 9.09
SecondaryPercent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 122.8 ± 0.16.2 ± 0.1
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 3.3 · 95% CI 3.03 to 3.60
SecondaryPercent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 121.7 ± 0.14.9 ± 0.1
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 3.2 · 95% CI 2.90 to 3.54
SecondaryPercent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 367.8 ± 0.215.2 ± 0.2
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 7.4 · 95% CI 6.84 to 7.89
SecondaryPercent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 363.5 ± 0.17.2 ± 0.1
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 3.7 · 95% CI 3.29 to 4.02
SecondaryPercent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36
percent changeAlendronate/AlendronateRomosozumab/Alendronate
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 362.4 ± 0.26.0 ± 0.2
Statistical analysis
  • Alendronate/Alendronate vs Romosozumab/Alendronate · ANCOVA · p = <0.001 · Ls mean difference: 3.6 · 95% CI 3.18 to 3.97

Adverse events

Collected over Double-blind treatment phase: 12 months. Overall study period: From first dose of study drug up to the end of study for participants who received at any open-label dose and up to the end of the double-blind period for participants who did not. The median duration of follow-up time was 36 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Period: Alendronate 70 mg QW22/2,014 (1.1%)278/2,014 (13.8%)1,190/2,014 (59.1%)
Double-blind Period: Romosozumab 210 mg QM30/2,040 (1.5%)262/2,040 (12.8%)1,112/2,040 (54.5%)
Overall Study: Alendronate / Alendronate103/2,014 (5.1%)638/2,014 (31.7%)1,498/2,014 (74.4%)
Overall Study: Romosozumab / Alendronate101/2,040 (5%)611/2,040 (30%)1,424/2,040 (69.8%)
Most frequent serious events
Showing 10 of 650
Most frequent serious events
EventDouble-blind Period: Alendronate 70 mg QWDouble-blind Period: Romosozumab 210 mg QMOverall Study: Alendronate / AlendronateOverall Study: Romosozumab / Alendronate
PneumoniaInfections and infestations17/201416/204046/201454/2040
Femur fractureInjury, poisoning and procedural complications12/201411/204051/201442/2040
Femoral neck fractureInjury, poisoning and procedural complications12/20145/204031/201415/2040
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders10/20145/204029/201424/2040
Cardiac failureCardiac disorders5/20145/204025/201418/2040
DeathGeneral disorders2/20141/204021/201414/2040
Urinary tract infectionInfections and infestations8/20148/204021/201421/2040
Radius fractureInjury, poisoning and procedural complications12/20148/204020/201414/2040
OsteoarthritisMusculoskeletal and connective tissue disorders5/20146/204011/201419/2040
Cerebrovascular accidentNervous system disorders7/20146/204015/201419/2040
Most frequent other events
Showing 10 of 23
Most frequent other events
EventDouble-blind Period: Alendronate 70 mg QWDouble-blind Period: Romosozumab 210 mg QMOverall Study: Alendronate / AlendronateOverall Study: Romosozumab / Alendronate
Viral upper respiratory tract infectionInfections and infestations233/2014217/2040406/2014388/2040
Back painMusculoskeletal and connective tissue disorders221/2014184/2040395/2014330/2040
ArthralgiaMusculoskeletal and connective tissue disorders193/2014165/2040380/2014343/2040
FallInjury, poisoning and procedural complications151/2014127/2040342/2014287/2040
Pain in extremityMusculoskeletal and connective tissue disorders129/2014121/2040253/2014230/2040
Urinary tract infectionInfections and infestations128/201497/2040244/2014180/2040
HypertensionVascular disorders130/2014113/2040232/2014233/2040
Upper respiratory tract infectionInfections and infestations132/2014130/2040226/2014205/2040
OsteoarthritisMusculoskeletal and connective tissue disorders111/2014113/2040206/2014189/2040
HeadacheNervous system disorders110/2014106/2040190/2014163/2040

Baseline characteristics

Age, Continuous
Age, Continuous(years)Alendronate/AlendronateRomosozumab/AlendronateTotal
Mean74.2 ± 7.574.4 ± 7.574.3 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Alendronate/AlendronateRomosozumab/AlendronateTotal
Female204720464093
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alendronate/AlendronateRomosozumab/AlendronateTotal
Hispanic or Latino6626311293
Not Hispanic or Latino138514152800
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alendronate/AlendronateRomosozumab/AlendronateTotal
American Indian or Alaska Native7512
Asian149137286
Black or African American231942
Native Hawaiian or Other Pacific Islander202
White141514472862
Multiple426
Other446436882
Missing101
Age Strata per Randomization
Age Strata per Randomization(Participants)Alendronate/AlendronateRomosozumab/AlendronateTotal
< 75 years9769731949
≥ 75 years107110732144
Severe Vertebral Fracture
Severe Vertebral Fracture(Participants)Alendronate/AlendronateRomosozumab/AlendronateTotal
Presence132113692690
Absence7266771403
Total Hip Bone Mineral Density (BMD) T-score
Total Hip Bone Mineral Density (BMD) T-score(Participants)Alendronate/AlendronateRomosozumab/AlendronateTotal
≤ -2.5138413562740
> -2.56626901352
Missing101
08

Study locations

317 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Peoria, Arizona 85381, United States
  • Research Site
    Phoenix, Arizona 85037, United States
  • Research Site
    Scottsdale, Arizona 85258, United States
  • Research Site
    Downey, California 90242, United States
  • Research Site
    Greenbrae, California 94904, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    South Lake Tahoe, California 96150, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Lakewood, Colorado 80227, United States
  • Research Site
    Fort Lauderdale, Florida 33309, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Stuart, Florida 34996, United States
  • Research Site
    West Palm Beach, Florida 33409, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Maywood, Illinois 60153, United States
  • Research Site
    Quincy, Illinois 62301, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Detroit, Michigan 48236, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Las Cruces, New Mexico 88011, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    Bismarck, North Dakota 58503, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Wyomissing, Pennsylvania 19610, United States
  • Research Site
    Richmond, Virginia 23233, United States
  • Research Site
    Port Angeles, Washington 98362, United States
  • Research Site
    Madison, Wisconsin 53705, United States
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1114, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1128AAF, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1430CKE, Argentina
  • Research Site
    Mar del Plata, Buenos Aires B7600DHK, Argentina
  • Research Site
    Quilmes, Buenos Aires B1878DVB, Argentina
  • Research Site
    Cordoba, Córdoba X5000BNB, Argentina
  • Research Site
    Buenos Aires, C1012AAR, Argentina
  • Research Site
    Darlinghurst, New South Wales 2010, Australia
  • Research Site
    Kogarah, New South Wales 2217, Australia
  • Research Site
    Randwick, New South Wales 2031, Australia
  • Research Site
    Box Hill, Victoria 3128, Australia
  • Research Site
    Geelong, Victoria 3220, Australia
  • Research Site
    Heidelberg West, Victoria 3081, Australia
  • Research Site
    Parkville, Victoria 3050, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Wien, 1060, Austria
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Bruxelles, 1000, Belgium
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4020, Belgium
  • Research Site
    Fortaleza, Ceará 60115-282, Brazil
  • Research Site
    Brasília, Distrito Federal 71625-009, Brazil
  • Research Site
    Vitória, Espírito Santo 29055-450, Brazil
  • Research Site
    Goiania, Goiás 74070-040, Brazil
  • Research Site
    Curitiba, Paraná 80030-110, Brazil
  • Research Site
    Recife, Pernambuco 52020-010, Brazil
  • Research Site
    Rio de Janeiro, 22271-100, Brazil
  • Research Site
    São Paulo, 04266-010, Brazil
  • Research Site
    São Paulo, 05437-010, Brazil
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sofia, 1202, Bulgaria
  • Research Site
    Sofia, 1421, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1504, Bulgaria
  • Research Site
    Sofia, 1612, Bulgaria
  • Research Site
    Sofia, 1709, Bulgaria
  • Research Site
    Vancouver, British Columbia V5Z 4E1, Canada
  • Research Site
    Winnipeg, Manitoba R3A 1M3, Canada
  • Research Site
    St. Johns, Newfoundland and Labrador A1B 3V6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Kitchener, Ontario N2M 1A1, Canada
  • Research Site
    Toronto, Ontario M5C 2T2, Canada
  • Research Site
    Toronto, Ontario M5G 2C4, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Research Site
    Westmout, Quebec H3Z 1E5, Canada
  • Research Site
    Quebec, G1V 3M7, Canada
  • Research Site
    Santiago, 8350595, Chile
  • Research Site
    Medellin, Antioquia 050021, Colombia
  • Research Site
    Barranquilla, Atlántico 08001000, Colombia
  • Research Site
    Bogota, Cundinamarca 11001000, Colombia
  • Research Site
    Bogota, Cundinamarca 110221, Colombia
  • Research Site
    Bogota, Cundinamarca, Colombia
  • Research Site
    Bogota, 11001000, Colombia
  • Research Site
    Bucaramanga, 68003, Colombia
  • Research Site
    Brno, 602 00, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Klatovy, 339 38, Czechia
  • Research Site
    Opava, 746 01, Czechia
  • Research Site
    Ostrava-Trebovice, 722 00, Czechia
  • Research Site
    Pardubice, 530 02, Czechia
  • Research Site
    Plzen, 305 99, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha 3, 130 00, Czechia

Showing the first 100 of 317 sites across 42 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. PubMed 28892457 ↗
  • Cosman F, Lewiecki EM, Ebeling PR, Hesse E, Napoli N, Matsumoto T, Crittenden DB, Rojeski M, Yang W, Libanati C, Ferrari S. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. J Bone Miner Res. 2020 Jul;35(7):1333-1342. doi: 10.1002/jbmr.3996. Epub 2020 May 22. PubMed 32445228 ↗
  • Lau EMC, Dinavahi R, Woo YC, Wu CH, Guan J, Maddox J, Tolman C, Yang W, Shin CS. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study. Osteoporos Int. 2020 Apr;31(4):677-685. doi: 10.1007/s00198-020-05324-0. Epub 2020 Feb 11. PubMed 32047951 ↗
  • Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20. PubMed 35466448 ↗
  • Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. J Bone Miner Res. 2021 Nov;36(11):2139-2152. doi: 10.1002/jbmr.4409. Epub 2021 Aug 10. PubMed 34190361 ↗
  • McClung MR, Betah D, Leder BZ, Kendler DL, Oates M, Timoshanko J, Wang Z. Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis. J Bone Miner Res. 2025 Feb 2;40(2):193-200. doi: 10.1093/jbmr/zjae194. PubMed 39656908 ↗
  • Ferrari S, Betah D, Feldman RG, Langdahl BL, Oates M, Timoshanko J, Wang Z, Dhaliwal R. Romosozumab Improves Tissue Thickness-Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes. J Clin Endocrinol Metab. 2025 Jan 24:dgae862. doi: 10.1210/clinem/dgae862. Online ahead of print. PubMed 39854280 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Feb 2017, 57 months.

Results were first posted in Dec 2018, 1 year 9 months after primary completion. A results delay was requested in Dec 2017.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 57 months is above that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2012
First posted
Jun 29, 2012
StartActual
May 4, 2012
Primary completionActual
Feb 27, 2017
CompletionActual
Jun 29, 2017
Results delay requested
Dec 11, 2017
Results first posted
Dec 12, 2018
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01631214
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 29, 2012
Start date
May 4, 2012
Primary completion
Feb 27, 2017
Completion
Jun 29, 2017
Results posted
Dec 12, 2018
Last update
Feb 21, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion